ALMRNasdaqLaboratory Analytical InstrumentsFiscal year ends December 31
Alamar Biosciences, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026
$26.30+1.02 (+4.03%)
Close on Oct 19, 2026
- Market cap
- $1.54B
- P/E (TTM)
- –
- Dividend yield
- –
About Alamar Biosciences
Laboratory Analytical Instruments, SIC 3826
Alamar Biosciences, Inc. is listed on Nasdaq under the ticker ALMR, in the SEC industry Laboratory Analytical Instruments. It is incorporated in Delaware and its fiscal year ends on December 31. Reported financials on StockData start in fiscal 2025.
Company profile
Company
- Legal name
- Alamar Biosciences, Inc.
- Headquarters
- Fremont, CA
- Address
- 47071 Bayside Parkway 94538
- Phone
- (510) 626-9888
- Website
- alamarbio.com
- Industry
- Laboratory Analytical Instruments
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
Stock & identifiers
- Ticker
- ALMR
- Exchange
- Nasdaq
- IPO date
- Apr 17, 2026
- Shares outstanding
- 69M, Jul 31, 2026
- Filer category
- <br>Emerging growth company
- SEC CIK
- 2104204
- CUSIP
- 010911105
- ISIN
- US0109111056
- EIN
- 36-4899036
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Yuling Luo | Chief Executive Officer, Director | 5,888,675 |
| Shiping Chen | Chief Operating Officer, Director | 1,445,770 |
| John L. Brottem | General Counsel | 29,000 |
| Timothy Ogden White | President | 491,803 |
| Justin J. McAnear | Chief Financial Officer | 37,220 |
| Robert P. Ragusa | Director | 5,686 |
| Rebecca Chambers | Director | – |
| Frank Witney | Director | – |
| Ian W. Ratcliffe | Director | – |
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Apr 17, 2026 | IPO | Initial public offering priced (424B4 prospectus) |
| Apr 15, 2026 | Listing | Registration of securities on an exchange (Form 8-A) |